Business
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
– Ironwood also presented results of a separate survey of nearly 90,000 Americans that highlights the prevalence and burden of multiple GI diseases – –
About this update from Ironwood Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Ironwood also presented results of a separate survey of nearly 90,000 Americans that highlights the prevalence and burden of multiple GI diseases –\n\n– Preclinical data presented at DDW highlight linaclotide’s effect on visceral hypersensitivity, which plays a key role in IBS-C –\n\n- Ironwood’s DDW presentations feature four posters of distinction –\n\n BOSTON--(BUSINESS WIRE)--\nIronwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, presented new findings at the Digestive Disease Week® (DDW) 2021 virtual meeting from a survey highlighting disease burden and care-seeking behavior among adult patients with irritable bowel syndrome with constipation (IBS-C) during the COVID-19 pandemic.\n\nThe poster presentation, titled Disease Burden and Care-Seeking Behavior for IBS-C Patients in the United States in the Era of COVID-19 (presentation number Fr014), summarized data from a cross-sectional online general health survey of 130 adults with IBS-C conducted from August through October 2020. More than a third of surveyed IBS-C patients indicated their symptoms had worsened during the COVID-19 pandemic. Additionally, nearly a quarter reported cancelling healthcare visits due to COVID-19. Also, nearly half (46%) of surveyed IBS-C patients reported that they did not seek care from a healthcare provider in the past year for their symptoms.\n\n“As a physician, my biggest takeaway from this survey is that while IBS-C patients’ symptoms have been exacerbated during the COVID-19 pandemic, they are unfortunately not speaking with their doctors, and hence the disease continues to have a wide impact despite availability of prescription treatment options,” said Brian E. Lacy, M.D., Ph.D., Gastroenterology, Neurogastroenterology, the Mayo Clinic. “It is critical for patients to recognize they have a legitimate medical condition that needs treatment and to take that step of speaking with their physician – either in person or through a telehealth appointment.”\n\nOther key findings from the survey, which was conducted in collaboration with researchers from the Mayo Clinic, the Acumen Health Research Institute and the International Foundation for Functional Gastrointestinal Disorders, include:\n\n\nSurveyed IBS-C patients reported a significantly higher proportion of moderate-to-severe anxiety and depression and significa...